California Medi-Cal GLP-1 Coverage (2026): The State Reversal That Removed Wegovy + Zepbound for Weight Loss

California Medi-Cal — the largest state Medicaid program in the United States — reversed course on GLP-1 anti-obesity coverage effective January 1, 2026. The enacted 2025-26 California State Budget directed the Department of Health Care Services (DHCS) to remove Wegovy, Zepbound, and Saxenda from the Medi-Cal Rx Contract Drugs List (CDL) for weight-loss and weight-loss-related indications. All previously approved prior authorizations (PAs) expired December 31, 2025; claims now deny with Reject Code 70 — Product/Service Not Covered, regardless of indication. Wegovy was added back to the CDL effective April 1, 2026 — but ONLY for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH); claims must be submitted with ICD-10-CM diagnosis code K76.0 or K75.8 or they deny with Reject Code 80. Zepbound for obstructive sleep apnea (OSA) and Wegovy for cardiovascular disease are reviewable case-by-case PA only. The seven T2D-indicated GLP-1s — Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, Trulicity — remain on the CDL with a Code I diagnosis restriction of type 2 diabetes (no PA required when the appropriate ICD-10-CM diagnosis code is on the pharmacy claim). Per the KFF January 2026 tracker, California is one of four states (with New Hampshire, Pennsylvania, and South Carolina) that eliminated Medicaid GLP-1 coverage for obesity treatment after the October 2025 KFF survey. The legal authority for the exclusion is the federal optional weight-loss-drug exclusion at 42 U.S.C. § 1396r-8(d)(2)(A).

The 2026 reversal: California's about-face on GLP-1 obesity coverage

California Medi-Cal previously covered anti-obesity medications (AOMs), including weight-management GLP-1s, under a generous-by-Medicaid-standards policy. The California Health Benefits Review Program (CHBRP) Final Draft analysis of SB 535, dated April 22, 2025, documents this directly:

“California has opted to cover anti-obesity medications (AOMs) for weight loss under its Medi-Cal program. Medi-Cal beneficiaries have coverage for GLP-1 medications with a U.S. Food and Drug Administration (FDA) indication for weight management. Quantity limits and labeler restrictions apply. Bariatric surgery and intensive behavioral therapy (IBT) are also covered as benefits under the Medi-Cal program.”

That description — accurate as of April 2025 — is no longer accurate. Effective January 1, 2026, the enacted 2025-26 California State Budget directed DHCS to end Medi-Cal Rx coverage of GLP-1 anti-obesity medications. The Medi-Cal Rx alert “Important Update: GLP-1s for Weight Loss Are Not a Covered Benefit” (October 21, 2025) cites the budget instrument as the operative authority:

“As announced in the alert titled 90-Day Countdown: Upcoming Changes to Medi-Cal Rx, and pursuant to the enacted 2025-26 State Budget, the Department of Health Care Services (DHCS) is implementing several Medi-Cal Rx policy updates to reduce pharmacy spending, improve program integrity, and ensure continued, equitable access to quality pharmacy benefits and services. One of these updates is that Medi-Cal Rx drug coverage is changing for GLP-1 drugs used for weight loss and weight-loss indications.”

The KFF January 16, 2026 state-by-state tracker corroborates the policy change from a third-party-survey angle: California is one of four states (with New Hampshire, Pennsylvania, and South Carolina) that “eliminated coverage of GLP-1s for obesity treatment” after the October 2025 KFF survey. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service arrangements per KFF — California is no longer on that list.

This is a budget-driven reversal, not a permanent statutory ban. California has elected to exercise the federal optional weight-loss-drug exclusion at 42 U.S.C. § 1396r-8(d)(2)(A) (discussed in detail below), and the policy instrument is the enacted state budget — not a standalone statute. A future legislative or budget cycle could reverse the reversal.

Bottom line: what Medi-Cal Rx covers (post-reversal)

The single most consequential fact for any Medi-Cal beneficiary or California prescriber working a GLP-1 prescription as of 2026:

• Type 2 diabetes-indicated GLP-1s (Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, Trulicity) remain covered without PA on the May 1, 2026 CDL with a Code I diagnosis restriction of type 2 diabetes — provided the appropriate ICD-10-CM diagnosis code is submitted on the pharmacy claim.
• Wegovy (semaglutide 2.4 mg) was added back to the CDL effective April 1, 2026 — but only for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Claims must be submitted with ICD-10-CM K76.0 or K75.8 or they deny with Reject Code 80. No PA is required when the diagnosis code is on the claim.
• Wegovy for cardiovascular disease is reviewable on a case-by-case PA basis only — no published BMI threshold, no published step-therapy requirement.
• Zepbound for obstructive sleep apnea (OSA) is reviewable on a case-by-case PA basis only — no published BMI threshold, no published step-therapy requirement. Zepbound is NOT on the May 1, 2026 CDL for any indication.
• Wegovy / Zepbound / Saxenda for weight loss are NOT covered for adults age 21 or older. Claims deny with Reject Code 70 — Product/Service Not Covered. All previously approved PAs expired December 31, 2025.
• Members under 21 retain access through the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit on a case-by-case PA basis, including for weight-loss indications.
• Foundayo (orforglipron — Eli Lilly's oral GLP-1 brand) is a direct-to-consumer cash-pay product that does not bill insurance; CDL status is irrelevant to the Foundayo patient pathway. Foundayo is not addressed in any Medi-Cal Rx primary source.

Wegovy for MASH (April 1, 2026 re-add) — ICD-10-CM K76.0 / K75.8 only

The Wegovy April 1, 2026 CDL re-add is the single most nuanced piece of California Medi-Cal Rx GLP-1 policy. Wegovy is on the CDL — but listed under the Miscellaneous section, not Hormones: Hypoglycemics — and is restricted to a single non-weight-loss indication. Verbatim from the May 1, 2026 CDL:

“Restricted to 1) the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) (formerly known as NASH); and 2) maximum quantity of 1 carton (4 single-dose pen injectors) per dispensing and one dispensing every 28 days. Also, restricted to NDC labeler code 00169 only.”

And from the GLP-1 Coverage Considerations alert (last updated April 6, 2026), the operational ICD-10-CM logic that the pharmacy claim must satisfy:

“Effective April 1, 2026, Wegovy does not require an approved prior authorization (PA) when prescribed for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH). Claims not submitted with the appropriate International Classification of Diseases — 10th Revision, Clinical Modification (ICD-10-CM) diagnosis code (K76.0 and/or K75.8) will deny with Reject Code 80 — Diagnosis Code Submitted Does Not Meet Drug Coverage Criteria. PA requests submitted for non-weight loss-related indications, such as cardiovascular disease, will be reviewed for coverage consideration based on medical necessity.”

Three things to know about the Wegovy MASH re-add:

1. The patient must have a documented MASH (or MASLD with steatohepatitis) diagnosis. The two ICD-10-CM codes that survive the diagnosis-restriction edit are K76.0 (Fatty (change of) liver, not elsewhere classified) and K75.8 (Other specified inflammatory liver diseases). The prescription claim must be submitted with one of these two diagnosis codes on the pharmacy claim record. Without one of these codes, the claim denies with Reject Code 80 at the point of sale.
2. No PA is required for the MASH indication. Unlike the case-by-case PA pathway for Wegovy under cardiovascular disease, the MASH indication is directly adjudicated at the pharmacy through the CDL diagnosis-restriction edit. The prescriber writes the prescription, the pharmacy submits the claim with K76.0 or K75.8, and the claim adjudicates. This is meaningfully easier than the cardiovascular pathway.
3. Quantity limit: 4 pens per 28 days. The maximum quantity is 1 carton (4 single-dose pens) per dispensing, with a 28-day refill interval. Higher quantities will be denied at the point of sale. This is the standard Wegovy package size and dosing interval.

YMYL boundary on the MASH coverage: the MASH diagnosis must be documented in the patient's medical record and the ICD-10-CM code must be on the pharmacy claim. We do not opine on whether a specific patient's clinical picture qualifies for K76.0 or K75.8 — that is a clinical determination by the treating prescriber, not a coverage analysis. If the patient does not have a MASH/MASLD diagnosis, this pathway is not available.

Zepbound for OSA: case-by-case PA only

Zepbound (tirzepatide) is NOT on the May 1, 2026 CDL for any indication. It was removed from the CDL effective January 1, 2026, and has not been added back. The only PA pathway is case-by-case review for the obstructive sleep apnea (OSA) indication. Verbatim from the GLP-1 Coverage Considerations alert:

“Effective January 1, 2026, claims for these drugs will deny with Reject Code 70 — Product/Service Not Covered regardless of indication. All previously approved PAs expired on December 31, 2025. PA requests for Zepbound will be considered when used for obstructive sleep apnea (OSA).”

And from the broader case-by-case framework in the October 21, 2025 alert (the original advance-notice alert):

“Medi-Cal Rx will review PA requests for these drugs for medical necessity in the following situations, on a case-by-case basis: For FDA-approved indications, limited to: Wegovy when used for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) or cardiovascular disease. Zepbound when used for obstructive sleep apnea (OSA). For members younger than 21 years of age pursuant to the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit.”

What “case-by-case” means in practice: the prescriber must submit a PA request to Medi-Cal Rx with the OSA diagnosis, polysomnography or home sleep apnea test evidence, AHI/apnea-hypopnea-index documentation, BMI/comorbidity documentation, and clinical justification for Zepbound vs alternative OSA therapies (CPAP, BiPAP, surgical interventions). The PA is reviewed individually. Medi-Cal Rx does not publish a fixed BMI threshold, a fixed AHI threshold, or a fixed step-therapy requirement for Zepbound OSA approvals.

YMYL boundary on Zepbound OSA coverage: we do not promise approval, do not promise a specific BMI cutoff, and do not promise a specific step-therapy requirement — because none is published in the verified Medi-Cal Rx primary sources. PA outcomes for Zepbound OSA are case-by-case and individual.

Wegovy / Zepbound / Saxenda for weight loss: NO

For adults age 21 or older, the three FDA-approved chronic- weight-management GLP-1 receptor agonists — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3 mg) — are NOT covered by Medi-Cal Rx for weight loss or weight-loss-related indications as of January 1, 2026. Verbatim from the GLP-1 Coverage Considerations alert:

“Effective January 1, 2026, the following drugs have been removed from the Medi-Cal Rx Contract Drugs List (CDL) and are no longer eligible for coverage for weight loss or weight loss-related indications: Zepbound [and] Saxenda.”

“Effective January 1, 2026, Wegovy is no longer eligible for coverage for weight loss or weight loss-related indications.”

“Effective January 1, 2026, claims for these drugs will deny with Reject Code 70 — Product/Service Not Covered regardless of indication. All previously approved PAs expired on December 31, 2025.”

And the unambiguous member-facing language from the State Budget Policy Updates FAQ (Question 19, April 6, 2026):

“No. The policy as of January 1, 2026, is that Medi-Cal Rx no longer covers GLP-1 drugs when used for weight loss or weight loss-related indications, regardless of the member's BMI.”

Three operational consequences:

1. Existing PAs expired December 31, 2025. Members who had an approved PA for Wegovy, Zepbound, or Saxenda for weight loss as of December 2025 lost coverage on January 1, 2026 — the PA did not roll over.
2. BMI does not change the answer. Per the FAQ above, the exclusion applies regardless of BMI. There is no BMI threshold (e.g., BMI ≥40, BMI ≥35 with comorbidities) that triggers Medi-Cal Rx coverage of Wegovy/Zepbound/Saxenda for weight loss for adults age 21 or older.
3. The MASH (Wegovy) and OSA (Zepbound) carve-outs do NOT cover weight-loss use. A member without documented MASH or OSA cannot use those carve-outs as a back-door coverage path for weight management. The diagnosis-restriction edits enforced at the point of sale (Reject Code 80 for MASH-without-K76.0/K75.8) are structurally designed to prevent this.

Saxenda has no surviving exception pathway for adults age 21 or older. There is no FDA-approved non-weight-management indication for Saxenda, so the case-by-case PA framework that preserves Wegovy CV / Wegovy MASH / Zepbound OSA coverage does not apply. The only Saxenda PA pathway is the EPSDT benefit for members under 21.

T2D-indicated GLP-1 coverage: 7 drugs, Code I diagnosis restriction, no PA

The seven type-2-diabetes-indicated GLP-1 receptor agonists remain on the May 1, 2026 CDL with a Code I diagnosis restriction of “type 2 diabetes mellitus.” Verbatim from the GLP-1 Coverage Considerations alert:

“The following GLP-1 drugs are currently on the CDL and continue to have a Code I diagnosis restriction of type 2 diabetes. Effective January 1, 2026, these drugs are no longer eligible for coverage for weight loss or weight loss-related indications: Ozempic®, Rybelsus®, Mounjaro®, Victoza®, Byetta, Bydureon®, Trulicity®.”

And from the State Budget Policy Updates FAQ Question 17 (the T2D-PA-process question):

“Weight loss and weight loss-related indications are no longer approved justifications for coverage approval. GLP-1 drugs prescribed for the treatment of type 2 diabetes that are currently listed on the Medi-Cal Rx Contract Drugs List (CDL) may be approved without a PA request. The ICD-10-CM diagnosis code must be submitted on the pharmacy claim for adjudication.”

For each of the seven T2D-indicated GLP-1s, the May 1, 2026 CDL also carries a labeler-code restriction. Verbatim examples (Ozempic, Mounjaro, Trulicity, and Bydureon listings):

Semaglutide (Ozempic): “Restricted to use in improving glycemic control in patients with type 2 diabetes mellitus and NDC labeler code 00169 only.”

Tirzepatide (Mounjaro): “Restricted to 1) use in improving glycemic control in patients with type 2 diabetes mellitus; and 2) maximum quantity of one carton (four single-dose pens) per dispensing and one dispensing every 28 days. Also restricted to NDC labeler code 00002 only.”

Dulaglutide (Trulicity): “Restricted to use in patients with type 2 diabetes mellitus and NDC labeler code 00002 only.”

Exenatide (Bydureon): “Restricted to use in the treatment of type 2 diabetes mellitus and NDC labeler code 00310 only for the Extended-Release Auto-Injector Pen.”

The labeler-code restrictions track the brand-name manufacturer NDCs (per the public NDC labeler registry; the CDL itself lists numeric codes only): NDC 00169 = Novo Nordisk (Ozempic, Rybelsus, Victoza), NDC 00002 = Eli Lilly (Mounjaro, Trulicity), NDC 00310 = AstraZeneca (Bydureon). These restrictions block third-party repackagers and substitute manufacturers but do not add clinical PA hurdles for the type-2-diabetes indication.

The statewide Medi-Cal Rx carve-out (January 1, 2022) — why plan-level divergence is structurally impossible

California carved its outpatient pharmacy benefit out of Medi-Cal managed-care plans into a single statewide fee-for-service pharmacy benefit branded “Medi-Cal Rx,” administered by Magellan Medicaid Administration (now operationally MedImpact; the Medi-Cal Rx Customer Service Center is operated by Prime Therapeutics per the contact information published in every DHCS alert). The carve-out went live January 1, 2022.

Why this matters for GLP-1 PA: regardless of which managed-care plan administers a Medi-Cal beneficiary's medical benefit — LA Care Health Plan, Health Net, IEHP, Kaiser Permanente Medi-Cal, Molina Healthcare of California, Anthem Blue Cross Medi-Cal, Blue Shield Promise, Central California Alliance for Health, or any other plan — all outpatient pharmacy PA decisioning is consolidated into Medi-Cal Rx. The Medi-Cal Rx CDL is the operative coverage list for every Medi-Cal beneficiary's GLP-1 prescription. Plan-level divergence (a beneficiary getting better PA criteria by switching from Health Net to Kaiser Permanente, or vice versa) is structurally impossible.

The CHBRP April 22, 2025 SB 535 analysis confirms this structural alignment (page 4):

“CHBRP generally assumes alignment of Medi-Cal Managed Care plan benefits, with limited exceptions.”

And the corresponding footnote:

“Although COHS plans are not subject to the Knox-Keene Act, DHCS generally updates Medi-Cal Managed Care plan contracts, All Plan Letters, and other appropriate authorities for alignment of managed care plan benefits, except in cases when the benefit is carved out of the Medi-Cal Managed Care plan contract or the law exempts specified Medi-Cal contracted providers.”

Plan-level confirmation comes from Central California Alliance for Health — a County Organized Health System (COHS) Medi-Cal plan in Monterey, Santa Cruz, San Benito, Mariposa, and Merced counties. Verbatim from its provider notice (verified 2026-05-09):

“Wegovy, Zepbound and Saxenda will be removed from the Contract Drugs List (CDL).”

The plan defers entirely to the Medi-Cal Rx CDL. No plan-specific divergence. This is the universal pattern across California Medi-Cal managed-care plans.

Contrast with Texas. In Texas (covered in our companion 50-state series article on Texas Medicaid), the state Vendor Drug Program (VDP) Preferred Drug List is operationalized through a managed-care system — STAR, STAR+PLUS, STAR Kids, STAR Health, CHIP — with plans like Aetna Better Health of Texas, Wellpoint, Molina, Superior HealthPlan, and UnitedHealthcare Community Plan administering the formulary. Texas managed-care plans operationally defer to the state VDP PDL but operate through plan-specific PBMs and PA fax workflows. California's centralized carve-out is a structurally different system: one statewide PBM, one CDL, one PA process.

The practical implication: a California Medi-Cal beneficiary denied a GLP-1 PA cannot improve outcomes by switching managed-care plans. The denial is at the Medi-Cal Rx layer, not the plan layer. The only escalation pathways are (a) the Medi-Cal Rx PA reconsideration process for the case-by-case indications (Wegovy CV, Zepbound OSA, EPSDT for under-21 members), (b) the State Hearing process administered by the California Department of Social Services, and (c) cash-pay alternatives outside the Medi-Cal benefit.

Failed legislation: SB 535 + AB 575 (historical context only)

Two California bills in the 2025-2026 legislative session sought to expand AOM coverage. Neither has changed Medi-Cal coverage, and the Medi-Cal Rx CDL reversal is the operative policy.

SB 535 (Senator Richardson) — Obesity Treatment Parity Act / Obesity Care Access Act. Status as of 2026-05-09 (per leginfo.legislature.ca.gov): “Engrossed” with “August 29 hearing postponed by committee” — the bill remains in Assembly Appropriations Committee. NOT signed, NOT vetoed; pending committee action. SB 535 would mandate commercial / CalPERS health insurance plans (DMHC- and CDI-regulated) to cover IBT, bariatric surgery, and at least one FDA-approved AOM for chronic weight management. It explicitly excludes Medi-Cal beneficiaries enrolled in DMHC-regulated plans. Verbatim from the CHBRP April 22, 2025 analysis (page 41):

“There would be no impact on Medi-Cal expenditures as SB 535 only applies to group and individual health plans, and would not affect the health insurance of any Medi-Cal beneficiaries, including those in managed care plans regulated by DMHC.”

SB 535 would not have changed Medi-Cal coverage even if signed. It is included here as historical context, not as a coverage pathway Medi-Cal beneficiaries can rely on.

AB 575 — Obesity Prevention Treatment Parity Act. Status as of 2026-05-09 (per leginfo.legislature.ca.gov): “Died pursuant to Art. IV, Sec. 10(c) of the Constitution” on January 31, 2026. Last substantive action: April 28, 2025 (first hearing canceled at author's request). The bill would have required commercial-plan coverage of IBT and at least one GLP-1 FDA-approved for the treatment or prevention of obesity. Bill failed.

Earlier prior-session bills referenced in the CHBRP analysis — SB 839 (2023, “held in the Assembly Health Committee without a hearing”) and SB 1008 (2024, “held in the Senate Appropriations Committee”) — both failed. None of these bills changed Medi-Cal coverage of weight-management GLP-1s in either direction.

The actual policy mechanism that ended Medi-Cal GLP-1 weight-loss coverage was NOT a standalone bill — it was the enacted 2025-26 California State Budget, signed by Governor Newsom. DHCS's October 21, 2025 alert cites “the enacted 2025-26 State Budget” as the authority for the policy change. Future budget cycles or freestanding obesity-coverage legislation could restore Medi-Cal AOM coverage; as of 2026-05-09, no such restoration is enacted.

Why weight-loss GLP-1s are excluded under federal law

Federal Medicaid drug-coverage rules permit — but do not require — states to exclude certain enumerated categories of drugs from coverage. The category that matters for Wegovy, Saxenda, and Zepbound (when prescribed for chronic weight management) is at 42 U.S.C. § 1396r-8(d)(2)(A). Verbatim:

“Agents when used for anorexia, weight loss, or weight gain.”

This is one of seven enumerated optional-exclusion categories in the statute (others include fertility, cosmetic, cough & cold, prescription vitamins, smoking-cessation, and DESI less-than-effective drugs). The federal floor: states may decline Medicaid coverage of any drug when prescribed for one of these uses. The federal ceiling: states may elect to cover them anyway — nothing prohibits state coverage.

California previously elected to cover anti-obesity GLP-1s for Medi-Cal beneficiaries. Effective January 1, 2026, California has elected to use the optional exclusion. The policy mechanism is the enacted 2025-26 State Budget; the operational implementation is the Medi-Cal Rx CDL revision and the Reject Code 70 / Reject Code 80 point-of-sale denial edits. The reversal is reversible — California can re-elect coverage in a future budget cycle.

Per the KFF January 16, 2026 tracker, only 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service as of January 2026. California is one of four states that “eliminated coverage of GLP-1s for obesity treatment” after the October 2025 KFF survey, alongside New Hampshire, Pennsylvania, and South Carolina. (North Carolina temporarily eliminated coverage in October 2025 but reinstated it in December 2025.)

How CalAIM dual-eligibles interact with Medicare Part D

Many California Medi-Cal beneficiaries with disabilities and most senior Medi-Cal beneficiaries are dual-eligible — they have both Medicare (the federal age-65+ / disability program) and Medi-Cal (the state Medicaid program). California's broader Medi-Cal transformation initiative, CalAIM (California Advancing and Innovating Medi-Cal), does not change the GLP-1 carve-out or the Medi-Cal Rx CDL. For dual-eligible Medi-Cal beneficiaries:

• Medicare Part D is the primary pharmacy payer. This is a long-standing federal rule, not California- specific. Medi-Cal Rx generally does not pay for prescription drugs that are within the Medicare Part D benefit.
• Medicare Part D has its own statutory exclusion of weight-loss drugs at Social Security Act § 1860D-2(e)(2)(A), which incorporates the same Medicaid optional-exclusion list (42 U.S.C. § 1396r-8(d)(2)). However, Medicare Part D may cover GLP-1 drugs used for FDA-approved indications other than weight loss alone (e.g., diabetes, cardiovascular event reduction, OSA in obesity). Plan-specific PA criteria apply.
• Wegovy under the cardiovascular event-reduction indication (FDA approved March 2024 for adults with established cardiovascular disease and obesity / overweight) is Part D-coverable on most Medicare Advantage Prescription Drug (MA-PD) and standalone Part D plans because the indication is non-weight-loss. PA criteria apply.
• Zepbound under the obstructive sleep apnea (OSA) indication (FDA approved December 2024 for moderate-to-severe OSA in obese adults) is similarly Part D-coverable on most MA-PD plans because the indication is non-weight-loss. PA criteria apply.
• Wegovy, Zepbound, Saxenda, and Foundayo under the chronic-weight-management indication are statutorily excluded from Medicare Part D coverage. Patients in this scenario have no Part D pathway to the weight-loss indication.
• T2D-indicated GLP-1s (Ozempic, Trulicity, Victoza, Mounjaro for T2D, Rybelsus for T2D) are Part D-coverable with PA on most MA-PD plans for the type-2-diabetes indication.

For dual-eligible California residents, the practical sequence is: check the Medicare Part D plan's formulary first, not the Medi-Cal Rx CDL. The Medicare Part D prescription is the operative coverage source. Medi-Cal covers the Medicare Part D copay (Medicare Savings Program / Qualified Medicare Beneficiary status) but does not directly pay the prescription. The Medi-Cal Rx GLP-1 weight-loss exclusion therefore primarily affects Medi-Cal- only beneficiaries (those without Medicare).

For a separate emerging pathway, the CMS Medicare GLP-1 Bridge demonstration is a voluntary short-term demonstration that has been announced to provide eligible Medicare Part D beneficiaries access to certain GLP-1 drugs (Wegovy, Zepbound) at a flat copayment between July 1, 2026 and December 31, 2027. We hedge the details here pending verbatim verification of the final program parameters; dual-eligible California Medi-Cal beneficiaries should consult their Medicare Part D plan and the cms.gov Medicare GLP-1 Bridge demonstration page directly for current terms.

How to appeal a Medi-Cal denial — State Hearing rights

If Medi-Cal Rx denies a GLP-1 PA after January 1, 2026, the member has the right to a State Hearing administered by the California Department of Social Services (CDSS). Verbatim from the State Budget Policy Updates FAQ:

“Medi-Cal members who receive a Notice of Action (NOA) denying coverage for GLP-1 drugs have the right to a State Hearing. Generally, Medi-Cal members have 90 days from the date of the NOA to submit a written request to the California Department of Social Services (CDSS) for a State Hearing, as communicated in the State Hearing rights provided with the NOA. Medi-Cal members who are taking GLP-1 drugs on or before January 1, 2026, who request a State Hearing within 10 days of receiving an NOA denying continued coverage may continue to receive GLP-1 drugs pending a State Hearing decision until the earlier of:
- The end of the period covered by their current PA; or
- The date a State Hearing decision is rendered; or
- The date on which the State Hearing is otherwise withdrawn or closed.”

Verbatim contact information:

“State Hearings
P.O. Box 944243, MS 21-37
Sacramento, CA 94244-2430
Toll Free: 1-800-743-8525 or 1-855-795-0634
Fax: 1-833-281-0905”

Two operational notes about the State Hearing pathway:

1. The 10-day “aid paid pending” window applies ONLY to members already taking the GLP-1 on or before January 1, 2026. A new requester — a member who never had an approved PA for the drug — does not get continued-coverage protection during the State Hearing process. The 90-day window to file the State Hearing request still applies, but the drug is not dispensed while the hearing is pending.
2. A State Hearing cannot fix a policy-level determination. Wegovy / Zepbound / Saxenda for weight-loss indications are excluded as a matter of Medi-Cal Rx policy under the enacted 2025-26 State Budget. A State Hearing is unlikely to overturn a properly adjudicated weight-loss-indication denial — the determination is policy-level, not clinical. Where a State Hearing may help is in the case-by-case PA framework: a Wegovy CV denial or a Zepbound OSA denial that the member believes was incorrectly adjudicated on medical-necessity grounds may be reviewed and potentially reversed at the hearing level.

For the broader appeal mechanics that apply across payers — including what to include in a Letter of Medical Necessity, how to engage with the verbatim policy clause cited in the denial, and how to coordinate a State Hearing with the prescriber's office — see our GLP-1 insurance dropped coverage appeal playbook. The four-phase appeal logic in that playbook applies directly to Medi-Cal Rx PA denials, with the State Hearing through CDSS substituted for the commercial-plan internal appeal pathway.

For patients without coverage: cash-pay options

California Medi-Cal beneficiaries whose weight-management GLP-1 prescription is not covered by Medi-Cal Rx — and beneficiaries for whom the case-by-case PA pathway will not succeed — have several manufacturer- and retailer-direct cash-pay options that do not require insurance. Verified 2026-05-09:

• NovoCare Pharmacy (Wegovy). Novo Nordisk self-pay program. Wegovy 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg single-dose pens at $299/month for cash-pay patients who do not have insurance or whose insurance does not cover Wegovy. Order through novocare.com.
• LillyDirect Self Pay Pharmacy (Zepbound). Eli Lilly direct-to-consumer vials. Zepbound 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg vials at $299–$449/month depending on dose strength. Ordered through lillydirect.com.
• LillyDirect / Amazon Pharmacy (Foundayo). Eli Lilly oral GLP-1 (orforglipron tablets) at $149/month. Foundayo is the direct-to-consumer cash-pay brand and does not bill insurance; Medi-Cal Rx CDL status is irrelevant to the Foundayo pathway.
• GoodRx and other discount-card programs. For T2D-indicated GLP-1s (Ozempic, Trulicity, Victoza), GoodRx coupons are a cash-pay fallback when Medi-Cal Rx PA is not the right pathway. Pricing varies by zip code and pharmacy; check goodrx.com for the patient's specific medication and local pharmacy.
• Compounded options. Compounded semaglutide and compounded tirzepatide from licensed 503A pharmacies run roughly $99–$300/month in the cash-pay market. Important regulatory caveat: the FDA enforcement-discretion period for compounded tirzepatide ended October 2024, and for compounded semaglutide ended February 2025. Compounding activity for these molecules is in a regulatory grey zone. The article does not name specific compounding pharmacies or telehealth vendors. Patients considering compounded options should verify the pharmacy's NPI, state board licensure, and product-quality testing before ordering.

The Members FAQ (Version 5.0, April 6, 2026) addresses the cash-pay question directly: members may pay out-of-pocket for GLP-1s and use discount cards that do not exclude Medi-Cal members — but Medi-Cal Rx will not reimburse out-of-pocket purchases for non-covered weight-loss use.

For more on the manufacturer-direct cash-pay landscape and the relationship between insurance pathways and self-pay options, see our GLP-1 insurance coverage across Medicare, Medicaid, and commercial deep-dive.

Bottom line

California Medi-Cal — the largest state Medicaid program in the United States — reversed course on GLP-1 anti-obesity coverage effective January 1, 2026. The policy authority is the enacted 2025-26 California State Budget; the operational mechanism is the Medi-Cal Rx CDL revision plus point-of-sale Reject Code 70 / Reject Code 80 denial edits. Wegovy, Zepbound, and Saxenda are no longer covered for weight loss for adults age 21 or older; all previously approved PAs expired December 31, 2025. Wegovy was added back to the CDL effective April 1, 2026 for MASH only — ICD-10-CM K76.0 or K75.8 must be on the pharmacy claim. Wegovy for cardiovascular disease and Zepbound for OSA are reviewable case-by-case PA only.

Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon, and Trulicity remain on the May 1, 2026 CDL with a Code I diagnosis restriction of type 2 diabetes; no PA is required for the T2D indication when an appropriate ICD-10-CM diagnosis code is on the pharmacy claim. The seven T2D incretins are the most reliably covered GLP-1 pathway in the post-reversal Medi-Cal Rx landscape.

Members under 21 retain access through the federal EPSDT benefit on a case-by-case PA basis, including for weight-loss indications. Dual-eligibles flow through Medicare Part D, not Medi-Cal Rx; Part D has its own framework allowing Wegovy CV and Zepbound OSA with PA, and excluding pure-weight-loss Wegovy/Zepbound/Saxenda/Foundayo statutorily.

California's outpatient pharmacy benefit was carved out of managed care into Medi-Cal Rx on January 1, 2022. The carve-out makes plan-level divergence (LA Care, Health Net, IEHP, Kaiser Permanente Medi-Cal, Molina, Anthem Blue Cross Medi-Cal, Blue Shield Promise, Central California Alliance for Health) structurally impossible. There is no plan-shopping pathway to better PA criteria. Failed legislation (SB 535 still pending in Assembly Appropriations and explicitly carved out Medi-Cal beneficiaries; AB 575 died January 31, 2026) does not change Medi-Cal coverage.

Members denied a GLP-1 PA may request a State Hearing through CDSS within 90 days of the Notice of Action; members already taking a GLP-1 on or before January 1, 2026 who request the hearing within 10 days of the NOA may continue to receive the drug pending the State Hearing decision (the “aid paid pending” window). Cash-pay alternatives include NovoCare Wegovy at $299/month, LillyDirect Zepbound at $299–$449/month, and Foundayo at $149/month.

The article makes no clinical recommendation, no plan- specific coverage promise, and no PA-success guarantee. Coverage and PA outcomes vary by individual clinical facts and current Medi-Cal Rx CDL revision. CDL status is as of the May 1, 2026 revision; updates are published periodically and CDL status is subject to change. Readers should call the Medi-Cal Rx Customer Service Center at 1-800-977-2273 (24/7/365) or check with their prescriber's office for an authoritative determination on any specific case.

Related research

• New York Medicaid (NYRx) GLP-1 coverage + Wegovy MACE pathway (2026) — companion 50-state Medicaid series article. The most structurally similar state to California: both have centralized statewide pharmacy carve-outs (Medi-Cal Rx Jan 1, 2022; NYRx April 1, 2023). New York's weight-loss exclusion is triple-anchored by federal statute, state regulation (18 NYCRR § 505.3(g)(3)), and explicit drug-brand-named NYRx contractor documentation — structurally stronger than California's budget-instrument-plus-federal-statute pairing. NYRx covers Wegovy only via a stricter-than-FDA- label MACE pathway (BMI ≥ 40, lifetime cap of 2 attempts).
• Texas Medicaid GLP-1 coverage + STAR+PLUS PA pathway (2026) — companion 50-state Medicaid series article. Texas has never covered weight-management GLP-1s and has plan-level discretion through STAR+PLUS managed-care plans (Aetna Better Health, Wellpoint, Molina, Superior HealthPlan, UnitedHealthcare Community Plan); California previously covered them, reversed in January 2026, and operates a centralized statewide carve-out that eliminates plan-level shopping.
• GLP-1 insurance coverage across Medicare, Medicaid, and commercial — the federal-state coverage framework, KFF state tracker, and how Wegovy/Zepbound/Foundayo actually flow through Medicare Part D and state Medicaid programs.
• GLP-1 insurance dropped coverage appeal playbook — the four-phase appeal logic that applies directly to Medi-Cal Rx PA denials, with the CDSS State Hearing substituted for the commercial-plan internal appeal pathway.
• Cigna GLP-1 prior-authorization guide — verbatim IP0206 / CNF 684 / CNF 360 coverage policies for Cigna's commercial-plan analog (and Cigna's California Medicare Advantage plans).
• Aetna GLP-1 prior-authorization guide — verbatim 4774-C / 6947-C / 1227-C coverage policies for Aetna's commercial-plan analog.
• Wegovy alternatives 2026 — for California Medi-Cal members whose Wegovy PA was denied for weight loss and who are evaluating Zepbound, Foundayo, Saxenda, and the cash-pay landscape.
• Zepbound alternatives 2026 — formulary-displaced patient profiles and the realistic alternatives when Zepbound is unavailable.
• Saxenda (liraglutide) evidence + Teva generic 2026 — the SCALE trial data and the August 2025 Teva generic liraglutide approval (the first FDA-approved generic GLP-1 for chronic weight management).
• GLP-1 prior-authorization letter generator — embeds verbatim payer-policy criteria into a Letter of Medical Necessity template usable for Medi-Cal Rx PA submissions and California State Hearing requests.